1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Refractory Burkitt Leukemia: new trials by email Literature Review of Refractory Burkitt Leukemia trials Research Report on Refractory Burkitt Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
Burkitt Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1)
Bortezomib (1) · CT-P10 (1) · Calcium Dobesilate (1) · Clofarabine (1) · Cyclophosphamide (1) · Dexamethasone (1) · Etoposide (1) · Rituximab (1) · Vincristine (1) · auricularum (1) · dexamethasone 21-phosphate (1) · dexamethasone acetate (1) · ofatumumab (1) · pegfilgrastim (1)
M.D. Anderson Cancer Center (1)
United States (1)
Maro Ohanian (1)